Effects of Cyclocarya paliurus (Batal.) Iljinskaja Polysaccharides on Lipid Metabolism and Expressions of PPARα, FAS, and GLUT4 mRNA in Hyperlipidemic Rats
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The effects of Cyclocarya paliurus (Batal.) Iljinskaja polysaccharides (CPPs) on the expression of genes related to lipid metabolism were examined in hyperlipidemic rats. Hyperlipidemic rats were randomly divided into hyperlipidemia model control, simvastatin, C. paliurus (CP) water extract group, low-dose CPP, moderate-dose CPP, and high-dose CPP groups (16 rats per group), and all rats were continuously fed for eight weeks. After the experiment, the total antioxidant capacity (T-AOC) and the contents of catalase (CAT), glutathione peroxidase (GSH-Px), and maleic dialdehyde (MDA) in the liver were measured. The mRNA expression levels of PPARα, FAS, and GLUT4 in the liver and adipose tissue were investigated by quantitative real-time polymerase chain reaction (qRT-PCR) to explore the hypolipemic mechanism of CPPs. All CPP-treated groups, irrespective of dose, and the CP water extract group exhibited decreased MDA in the liver after treatment, and the most significant reduction was observed in the high-dose CPP group (53.47% decrease; P < 0.01). The T-AOC value and the contents of CAT and GSH-Px increased in all CPP-treated groups and the CP water extract group (P < 0.01), and the largest increases were 112.05%, 48.63%, and 6.17%, respectively. In addition, each CPP-treated group exhibited increased mRNA expression levels of PPARα and GLUT4 after treatment (P < 0.05, P < 0.01), and the highest increases in the liver were 19.45% and 35.50%, respectively. All CPP-treated groups had decreased FAS mRNA expression, and the largest declines observed in the liver and adipose tissue were 25.02% and 20.49%, respectively. These results indicated that CPP has inhibitory effects on lipid oxidation in the liver and regulates the expression of genes related to lipid metabolism, thus alleviating hyperlipidemia.
